Media banner

Video &  Social Media

Watch us in interviews. Follow us.


Group Secures $5.1M to Expand Platform for COVID Research

NEW YORK, December 21, 2020 – Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is a member of the Canadian national COVID Cloud consortium. 

The platform will be used by MRI to help understand, predict, and treat COVID-19 with molecular precision.

MRI is developing a host-directed approach to treating patients with COVID-19 suffering from Acute Respiratory Distress Syndrome (ARDS).  MRI is contributing to the development of the COVID-19 platform so as to provide information that will improve the effectiveness of its novel therapeutic for COVID-19 patients, code named MAN-19.  

The Canadian national consortium will expand development of a software platform for genomics and health data and apply it to COVID-19 research and drug development utilizing $5.1M CAD in co-funding by Canada’s Digital Technology Supercluster and aims to increase Canada’s capacity to harness exponentially growing volumes of genomics and biomedical data to advance precision health.  With a global death count of over 1.4 million people and record numbers of cases nationally, solutions that can help Canada respond to ongoing challenges of the pandemic are urgently needed.

The consortium is a collaboration between BioSymetrics, Centre of Genomics and Policy at McGill University, DNAstack, FACIT, Genome BC, Mannin Research, McMaster University, Microsoft Canada, Ontario Genomics, Ontario Institute for Cancer Research, Roche Canada, Sunnybrook Research Institute, and Vector Institute. It leverages past work of partners to address needs of infectious disease research with guidance from domain experts.

“We are very proud to contribute to such an important effort in Canada, as it will have an impact not only on Canadian’s healthcare but on COVID-19 patients around the world, as we learn more about the disease and ways we can treat patients with it”, said George N. Nikopoulos, President and CEO of Mannin Research Inc.

For more information, visit

About Mannin Research Inc.

Mannin Research is a research-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases. Mannin Research main platform is built on the expertise in activation of Angiopoietin-Tie2 signalling pathway, a major regulator of vascular endothelium with a broad range of therapeutic applications.

Acute respiratory distress syndrome (ARDS) is a major severe complication of viral respiratory infections and the primary cause of mortality of COVID-19 patients. It is associated with profound vascular inflammation leading to pulmonary edema and hypoxemic respiratory failure. In the face of the global COVID-19 pandemic, Mannin Research is developing novel therapeutics to stabilize lung endothelial barrier integrity and reduce vascular leakage. These therapeutics offer novel virus-independent, host-directed strategies to support patients with critical respiratory illness and prevent negative outcomes.

About Digital Technology Supercluster

The Digital Technology Supercluster solves some of industry's and society's biggest problems through Canadian-made technologies. We bring together private and public sector organizations of all sizes to address challenges facing Canada's economic sectors including healthcare, natural resources, manufacturing and transportation. Through this 'collaborative innovation' the Supercluster helps to drive solutions better than any single organization could on its own.  The Digital Technology Supercluster is led by industry leaders such as D-Wave, Finger Food Advanced Technology Group, LifeLabs, LlamaZOO, Lululemon, MDA, Microsoft, Mosaic Forest Management, Sanctuary AI, Teck Resources Limited, TELUS, Terramera, and 1Qbit. Together, we work to position Canada as a global hub for digital innovation. A full list of Members can be found here.

About the COVID-19 Program

The COVID-19 Program aims to improve the health and safety of Canadians and support Canada's ability to address issues created by the COVID-19 outbreak. In addition, the program will build expertise and capacity to anticipate and address issues that may arise in future health crises, from healthcare to a return to work and community. More information can be found here.

Please visit for more information on our various pipeline products.

About Q BioMed Inc.
Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Denis Corin CEO Q BioMed Inc. +1(646) 884-7017

Investor Relations:
Keith Ppinder
+1(404) 995-6671 This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Source: Q BioMed Inc.